NO20004104L - Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater - Google Patents

Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater

Info

Publication number
NO20004104L
NO20004104L NO20004104A NO20004104A NO20004104L NO 20004104 L NO20004104 L NO 20004104L NO 20004104 A NO20004104 A NO 20004104A NO 20004104 A NO20004104 A NO 20004104A NO 20004104 L NO20004104 L NO 20004104L
Authority
NO
Norway
Prior art keywords
preparations
viruses
methods
concentrating virus
concentrating
Prior art date
Application number
NO20004104A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004104D0 (no
Inventor
John Chu-Tay Tang
Andreas Frei
Henry K H Kwan
Varda E Sandweiss
Gary J Vellekamp
Pui-Ho Yuen
Jr Laureano L Bondoc
Iv Frederick William Porter
Peter M Ihnat
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20004104D0 publication Critical patent/NO20004104D0/no
Publication of NO20004104L publication Critical patent/NO20004104L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20004104A 1998-02-17 2000-08-16 Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater NO20004104L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Publications (2)

Publication Number Publication Date
NO20004104D0 NO20004104D0 (no) 2000-08-16
NO20004104L true NO20004104L (no) 2000-10-17

Family

ID=26698472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004104A NO20004104L (no) 1998-02-17 2000-08-16 Preparater omfattende virus og fremgangsmater for konsentrering av viruspreparater

Country Status (25)

Country Link
EP (4) EP1054955B1 (de)
JP (3) JP4358434B2 (de)
KR (5) KR100862169B1 (de)
CN (2) CN101164623B (de)
AR (3) AR020054A1 (de)
AT (3) ATE341614T1 (de)
AU (1) AU757976B2 (de)
BR (1) BR9908015A (de)
CA (2) CA2320419C (de)
CO (1) CO4820440A1 (de)
DE (3) DE69936948T2 (de)
DK (1) DK1054955T3 (de)
ES (2) ES2272053T3 (de)
HK (3) HK1028416A1 (de)
HU (1) HU226015B1 (de)
ID (1) ID28298A (de)
IL (2) IL137510A0 (de)
MY (1) MY141641A (de)
NO (1) NO20004104L (de)
PE (1) PE20000265A1 (de)
PL (1) PL197747B1 (de)
PT (1) PT1054955E (de)
SK (1) SK11842000A3 (de)
TW (1) TWI232107B (de)
WO (1) WO1999041416A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP1707631A3 (de) 1996-11-20 2006-12-27 Introgen Therapeutics, Inc. Ein verbessertes Verfahren zur Produktion und Reinigung von adenoviralen Vektoren
EP1977764A1 (de) * 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Adenovirusformulierung für die Gentherapie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU4346101A (en) * 2000-03-07 2001-09-17 Merck & Co., Inc. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A8 (en) * 2000-12-12 2008-01-17 Japan Tobacco Inc Pharmaceutical composition containing an active with a hemolytic action and a surfactant
EP1453537A1 (de) 2001-12-12 2004-09-08 FH Faulding & Co. Limited Zusammensetzung zur konserverierung von viren
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
AR038153A1 (es) * 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
KR20070104339A (ko) 2004-11-03 2007-10-25 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
CN101155915B (zh) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
CA2633087C (en) 2005-12-12 2014-12-02 Canji, Inc. Adenoviral expression vectors
BRPI0710820A2 (pt) * 2006-04-20 2011-08-23 Wyeth Corp processo para a purificação do vìrus da estomatite vesicular (vsv) do fluido de cultura celular de uma cultura de células de mamìferos infectada com vsv; vsv purificado de acordo com o processo; composição farmacêutica; e composição imunogênica
MX2011004292A (es) 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
SG175409A1 (en) 2009-05-02 2011-12-29 Genzyme Corp Gene therapy for neurodegenerative disorders
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ad 26 아데노바이러스 벡터를 제조하는 방법
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
TW201233802A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
SG194449A1 (en) * 2011-04-29 2013-12-30 Oncolytics Biotech Inc Methods of purifying viruses using gel permeation chromatography
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Rsvに対するワクチン
ES2715378T3 (es) 2013-04-25 2019-06-04 Janssen Vaccines & Prevention Bv Polipéptidos F de prefusión del virus sincicial respiratorio (RSV) solubles y estabilizados
BR112015031509B1 (pt) 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
JP2017519734A (ja) * 2014-05-28 2017-07-20 エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ ウイルスの減少方法
EP3283634B1 (de) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Rekombinantes adenovirus mit expression von zwei transgenen mit einem bidirektionalen promotor
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された可溶性融合前rsv fポリペプチド
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
AU2017272504A1 (en) 2016-05-30 2018-11-29 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
BR112018075969A2 (pt) 2016-06-20 2019-04-02 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
EP3484506A1 (de) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv-impfstoffe
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
EP3681533A1 (de) 2017-09-15 2020-07-22 Janssen Vaccines & Prevention B.V. Verfahren zur sicheren induktion der immunität gegen rsv
WO2020264411A1 (en) * 2019-06-28 2020-12-30 Baxalta Incorporated Adeno-associated virus purification methods
BR112022014808A2 (pt) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前rsv fb抗原
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (de) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
KR20090127947A (ko) 2009-12-14
KR20010072547A (ko) 2001-07-31
KR101018992B1 (ko) 2011-03-07
HK1073481A1 (en) 2005-10-07
DE69942708D1 (de) 2010-10-07
KR100912362B1 (ko) 2009-08-19
DE69933433D1 (de) 2006-11-16
KR20080065614A (ko) 2008-07-14
HUP0100670A2 (hu) 2001-06-28
IL137510A (en) 2012-10-31
WO1999041416A3 (en) 1999-11-18
IL137510A0 (en) 2001-07-24
JP4358434B2 (ja) 2009-11-04
AR063315A2 (es) 2009-01-21
EP1526173B1 (de) 2012-11-21
CO4820440A1 (es) 1999-07-28
EP1526173A2 (de) 2005-04-27
ATE341614T1 (de) 2006-10-15
SK11842000A3 (sk) 2001-05-10
EP1526174A2 (de) 2005-04-27
DE69936948D1 (de) 2007-10-04
EP1526174A3 (de) 2005-08-31
EP1054955B1 (de) 2006-10-04
DE69933433T2 (de) 2007-08-23
ATE478945T1 (de) 2010-09-15
PL342847A1 (en) 2001-07-16
CA2320419A1 (en) 1999-08-19
JP2010213727A (ja) 2010-09-30
KR100991683B1 (ko) 2010-11-04
BR9908015A (pt) 2001-04-24
ATE371020T1 (de) 2007-09-15
CN101164623A (zh) 2008-04-23
KR100918187B1 (ko) 2009-09-22
MY141641A (en) 2010-05-31
EP1526173A3 (de) 2005-08-10
EP1741777A1 (de) 2007-01-10
ID28298A (id) 2001-05-10
CN100374551C (zh) 2008-03-12
PT1054955E (pt) 2007-01-31
HU226015B1 (en) 2008-02-28
EP1054955A2 (de) 2000-11-29
HUP0100670A3 (en) 2003-10-28
NO20004104D0 (no) 2000-08-16
AU757976B2 (en) 2003-03-13
AU2653899A (en) 1999-08-30
DK1054955T3 (da) 2007-01-15
HK1097413A1 (en) 2007-06-22
CN101164623B (zh) 2012-11-14
EP1526174B1 (de) 2007-08-22
ES2272053T3 (es) 2007-04-16
AR063314A2 (es) 2009-01-21
AR020054A1 (es) 2002-04-10
CA2320419C (en) 2011-02-08
KR20080065615A (ko) 2008-07-14
WO1999041416A2 (en) 1999-08-19
JP2002503484A (ja) 2002-02-05
EP1741777B1 (de) 2010-08-25
PE20000265A1 (es) 2000-04-25
KR20090038927A (ko) 2009-04-21
KR100862169B1 (ko) 2008-10-09
HK1028416A1 (en) 2001-02-16
CN1297478A (zh) 2001-05-30
DE69936948T2 (de) 2008-05-15
ES2290613T3 (es) 2008-02-16
CA2723040A1 (en) 1999-08-19
JP2006166925A (ja) 2006-06-29
PL197747B1 (pl) 2008-04-30
TWI232107B (en) 2005-05-11

Similar Documents

Publication Publication Date Title
NO20004104D0 (no) Preparater omfattende virus og fremgangsmÕter for konsentrering av viruspreparater
PT773957E (pt) Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
NO983965D0 (no) Polymer-organoleire-kompositter og deres fremstilling
NO20005839D0 (no) Preparater for behandling av HIV og andre virale infeksjoner
DK0729956T3 (da) Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
FI963717A0 (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
EP1127169A4 (de) Detektion minussträngiger rna-viren
DE60035497D1 (de) Verfharen zur konservierung von viren und mycoplasma
NO20011162L (no) Fremgangsmåter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
ZA200202816B (en) Modified plant viruses and methods of use thereof.
NO971495L (no) Svekkede virus og fremgangsmåte til deres fremstilling
DE60031826D1 (de) Trennung von Viren und Nachweis von Viren
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
DE69714504D1 (de) Benzothiopene, diese enthaltende Zubereitungen und Verfahren
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
GB9809666D0 (en) Modified viruses
NO991227D0 (no) PTX-sensitive G-proteiner, deres fremstilling og bruk
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.
DE69519722D1 (de) Wirkstof gegen viren und krebs
BR9506962A (pt) Cultura seletiva de virus
DE69824881D1 (de) Kompakte replikons des epstein-barr-virus.
IS5778A (is) Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar
GB9908224D0 (en) Virus preparations and methods
AU5082698A (en) Heat inactivation of viruses in antibody preparations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application